FOXM1 and gastric neoplasm: Specifically, we have demonstrated that 1) GPC3 has a prognostic value and low expression levels correlate with poor clinical outcome; 2) loss of GPC3 increases the invasive capacity of tumor cells; 3) GPC3 expression is lost in metastatic lesions in the lymph nodes regardless of GPC3 expression in primary tumors; 4) GPC3 signals downstream to MAPK/FoxM1 to regulate the cellular invasion program and 5) GPC3 and FoxM1 inversely correlate in primary gastric tumors.